1. Incidental uptake of 18F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancerMarina Hodolič, Jurij Fettich, 2014, original scientific article Abstract: Background. Positron emission tomography-computed tomography (PET/CT) with 18F-fluorocholine (FCH) is routinely performed in patients with prostate cancer. In this clinical context, foci of FCH uptake in the head or in the neck were considered as incidentalomas, except for those suggestive of multiple bone metastases. Case reports. In 8 patients the incidental focus corresponded to a benign tumour. The standard of truth was histologyin two cases, correlative imaging with MRI in four cases, 99mTc-SestaMIBI scintigraphy, ultrasonography and biochemistry in one case and biochemistry including PTH assay in one case. The final diagnosis of benign tumoursconsisted in 3 pituitary adenomas, 2 meningiomas, 2 hyperfunctioning parathyroid glands and 1 thyroid adenoma. Malignancy was proven histologically in 2 other patients: 1 papillary carcinoma of the thyroid and 1 cerebellar metastasis.Conclusions. To the best of our knowledge, FCH uptake by pituitary adenomas or hyperfunctioning parathyroidglands has never been described previously. We thus discuss whether there might be a future indication for FCH PET/CT when one such tumour is already known or suspected: to detect a residual or recurrent pituitary adenoma aftersurgery, to guide surgery or radiotherapy of a meningioma or to localise a hyperfunctioning parathyroid gland. Inthese potential indications, comparative studies with reference PET tracers or with 99mTc-sestaMIBI in case of hyperparathyroidism could be undertaken.
Keywords: FCH, PET/CT, incidentaloma, meningioma, pituitary adenoma, hyperparathyroidism, thyroid adenoma
Published in DiRROS: 10.04.2024; Views: 71; Downloads: 17
 Full text (991,90 KB) |
2. Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer : a dual centre surveyMarina Hodolič, Laure Michaud, V. Huchet, S. Balogova, V. Nataf, K. Kerrou, M. Vereb, Jurij Fettich, Jean-Noël Talbot, 2014, original scientific article Abstract: Background. Fluorocholine(18F) (FCH) was introduced at the beginning of April 2010 in France, Slovenia and three other EU member states for the localisation of bone metastases of prostate cancer with PET. The aim of the study was to compare the evolution of diagnostic imaging in patients with prostate cancer using a new radiopharmaceutical FCH, observed in France and in Slovenia, and to quantify the consequence of the results of new imaging modality on the detection rate of abnormal metastases and recurrences of prostate cancer.Patients and methods. In two centres (France/Slovenia), a survey of the number of nuclear medicine examinations in patients with prostate cancer was performed, covering 5 quarters of the year since the introduction of FCH. For each examination, the clinical and biological circumstances were recorded, as well as the detection of bone or soft tissue foci.Results. Six hundred and eighty-eight nuclear medicine examinations were performed impatients with prostate cancer. Nuclear medicine examinations were performed for therapy monitoring and follow-up in 23% of cases. The number of FCH PET/CT grew rapidly between the 1st and 5th period of the observation (+220%), while the number of bone scintigraphies (BS) and fluoride(18F) PET/CTs decreased (-42% and -23% respectively). Fluorodeoxyglucose(18F) (FDG) PET/CT remained limited to few cases of castrate-resistant or metastatic prostate cancer in Paris. The proportion of negative results was significantly lower with FCH PET/CT (14%) than with BS (49%) or fluoride(18F) PET/CT (54%). For bone metastases, the detection rate was similar, but FCH PET/CT was performed on average at lower prostate-specific antigen (PSA) levels and was less frequently doubtful (4% vs. 28% for BS). FCH PET/CT also showed foci in prostatic bed (53% of cases) or in soft tissue (35% of cases).Conclusions. A rapid development of FCH PET/CT was observed in both centres and led to a higher detection rate of prostate cancer lesions.
Keywords: prostate cancer, PET/CT, fluorocholine (FCH), fluoride(18F), bone scintigraphy, indication of imaging, prostata, rak (medicina), slikovna diagnostika
Published in DiRROS: 04.04.2024; Views: 71; Downloads: 38
Full text (595,04 KB)
This document has many files! More... |
3. Rople of [sup]18F-choline PET/CT in evaluation of patients with prostateMarina Hodolič, 2011, original scientific article Abstract: Background. Choline presents a high affinity for maligna nt prostate tissue. It can be labelled with positron emitting 18f,and used for the evaluation of patients with prostate carcinoma by PET/CTimaging. The aim of this paper is tosummarise our experience with fluoromethylcholine ('8f-choline) PET/CTin patients with prosta te cancer. Methods. In 4 months we investigated the patients with histopathological (or cytological) confirmed prosta te cancer. Two observers evaluated the early and late 18f-choline PETimages in correlation with corresponding localising CT images and using the semiquantitative standard uptake value (SUV)calculation. Results. The 18f-choline PET/CT was made in 50 patients with prosta te cancer. There were 18 patients after radical prostatectomy and 32 without surgery.ln allpatients wiff1but surgery the pathological uptake was seen in the prostate. ln 14 (44 %) patients of this group there was evidence of metastatic spread in local or distant Iymph nodes and/or bones. In out of 18 patients after radical prostatectomy the local recurrence was detected in 6 patients (33%) and distant metastases were present in 2 patients (10%). Conclusions. 18f-choline PET/CTseems to be useful imaging modality in patients with prosta te carcinoma; it can demonstrate spread of the disease preoperatively and detect the local recurrence after radical prostatectomy.
Published in DiRROS: 19.03.2024; Views: 66; Downloads: 21
Full text (547,29 KB) |
4. |
